Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
...
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1
- Registration Number
- NCT05005273
- Locations
- 🇫🇷
Local Institution - 0044, Pessac, France
🇫🇷Local Institution - 0013, Suresnes, France
🇫🇷Local Institution - 0042, Toulon, France
Axitinib + Ipilimumab in Advanced Melanoma
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2024-11-28
- Target Recruit Count
- 25
- Registration Number
- NCT04996823
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma
- Conditions
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 60
- Registration Number
- NCT04988841
- Locations
- 🇫🇷
Hôpital Nantes Hôtel Dieu, Nantes, France
🇫🇷Hôpital Saint Louis, Paris, France
🇫🇷Hôpital Gustave Roussy, Villejuif, France
Combination Immunotherapy in Rare Cancers Under InvesTigation
- Conditions
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Olivia Newton-John Cancer Research Institute
- Target Recruit Count
- 240
- Registration Number
- NCT04969887
- Locations
- 🇳🇿
Auckland City Hospital, Auckland, New Zealand
🇦🇺Blacktown Hospital, Sydney, New South Wales, Australia
🇦🇺Fiona Stanley Hospital, Perth, Western Australia, Australia
Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 6
- Registration Number
- NCT04967196
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 5
- Registration Number
- NCT04966676
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
- Conditions
- Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Ureter Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic MelanomaMetastatic Renal Pelvis Urothelial CarcinomaMetastatic Ureter Urothelial CarcinomaPathologic Stage IIID Cutaneous Melanoma AJCC v8Stage III Urethral Cancer AJCC v8Locally Advanced Bladder CarcinomaLocally Advanced Renal Pelvis Urothelial Carcinoma
- Interventions
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT04940299
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
- Conditions
- Interventions
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 13
- Registration Number
- NCT04938232
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸University of Chicago Medicine, Chicago, Illinois, United States
BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
- Conditions
- Interventions
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Brown University
- Target Recruit Count
- 25
- Registration Number
- NCT04933903
- Locations
- 🇺🇸
Rhode Island Hospital, Providence, Rhode Island, United States
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
- Conditions
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 427
- Registration Number
- NCT04929041
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.